J&J and Elan lower deal price as Elan moves to appease Biogen
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has renegotiated its $1.5 billion investment in Elan to acquire a 18.4% stake in the Irish company and funding for certain clinical programmes, cutting the price by $115 million.